REG - Tissue Regenix Group - 2023 LTIP Grant

Tissue RegenixAnnouncement

23/01/2024 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240123:nRSW6727Aa&default-theme=true

RNS Number : 6727A  Tissue Regenix Group PLC  23 January 2024

 Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

2023 LTIP Grant

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial
Officer, were each granted an award of restricted share units ("RSUs") with
respect to ordinary shares in the capital of the Company ("Ordinary Shares")
on 21 March 2023, under the Company's existing Long-Term Incentive Plan,
following the publication of its 2022 results.

 

Daniel Lee was awarded 19,807,390 RSUs (subsequently reduced to 198,073 RSUs
following the Company's share consolidation that became effective on 28 April
2023) and David Cocke has been awarded 15,367,803 RSUs (subsequently reduced
to 153,678 RSUs), where each RSU that vests shall represent the right to
receive payment of one Ordinary Share. The exercise price of the RSUs was 0.1p
per Ordinary Share (subsequently adjusted to 10p). The RSUs are subject to
continued service over a period of three years and satisfaction of customary
performance conditions relating to growth in total shareholder return, annual
revenue targets, annual profitability targets and personal performance
targets, further details of which will be set out in the Company's 2023 Annual
Report.

 

Following the grant of these options, Daniel Lee and David Cocke hold options
over a total of 756,897 and 514,002 RSUs respectively representing 1.1% and
0.7% of the current issued share capital respectively.

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                               via Walbrook PR

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Charlotte Edgar / Alice Woodings                                   TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissueregenix.com (https://www.tissueregenix.com) )

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation ('dCELL®')
technology removes DNA and other cellular material from animal and human soft
tissue leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or worn-out body parts.
Current applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech
company that specializes in regenerative medicine and is dedicated to the
development of innovative osteoinductive and soft tissue scaffolds that
enhance healing opportunities of defects created by trauma and disease.
CellRight's human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated ("PCA")
with them.

    1     Details of the person discharging managerial responsibilities / person closely

        associated

 a)       Name                                                         Daniel Lee

 2        Reason for the notification

 a)       Position/status                                              CEO

 b)       Initial notification /Amendment                              Initial notification

 3        Details of the issuer, emission allowance market participant, auction

        platform, auctioneer or auction monitor

 a)       Name                                                         Tissue Regenix Group plc

 b)       LEI                                                           213800PNOD5UHQUFJI36

 4        Details of the transaction(s): section to be repeated for (i) each type of

        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
          place where transactions have been conducted
 a)       Description of the financial instrument, type of instrument  Restricted share units ("RSUs") with respect to ordinary shares in the capital

                                                            of the Company of 0.1p

 b)       Identification code                                          GB00B5SGVL29

 c)       Nature of the transaction                                    Issue of options

 d)       Price(s) and volume(s)                                       Volume(s):

                                                                       19,807,390 RSUs

                                                                       Price: 0.1 pence per RSU
 d)       Aggregated information

          - Aggregated volume                                          19,807,390

          - Price                                                      £19,807.39
 e)       Date of the transactions                                     21 March 2023

 f)       Place of the transaction                                     Outside of a trading venue

 

    1     Details of the person discharging managerial responsibilities / person closely

        associated

 a)       Name                                                         David Cocke

 2        Reason for the notification

 a)       Position/status                                              CFO

 b)       Initial notification /Amendment                              Initial notification

 3        Details of the issuer, emission allowance market participant, auction

        platform, auctioneer or auction monitor

 a)       Name                                                         Tissue Regenix Group plc

 b)       LEI                                                           213800PNOD5UHQUFJI36

 4        Details of the transaction(s): section to be repeated for (i) each type of

        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
          place where transactions have been conducted
 a)       Description of the financial instrument, type of instrument  Restricted share units ("RSUs") with respect to ordinary shares in the capital

                                                            of the Company of 0.1p

 b)       Identification code                                          GB00B5SGVL29

 c)       Nature of the transaction                                    Issue of options

 d)       Price(s) and volume(s)                                       Volume(s):

                                                                       15,367,803 RSUs

                                                                       Price: 0.1 pence per RSU
 d)       Aggregated information

          - Aggregated volume                                          15,367,803

          - Price                                                      £15,367.80
 e)       Date of the transactions                                     21 March 2023

 f)       Place of the transaction                                     Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDXLFLZFLLBBL